CORT Insiders Are Giving Away Shares—Not Selling—As Legal and FDA Storms Gather

The legal backdrop for Corcept is now clear. A securities class action lawsuit, filed in February, alleges that executives misrepresented the strength of clinical trial data for the drug relacorilant and hid repeated FDA warnings. The suit covers the period from October 31, 2024, to December 30, 2025-a timeframe that includes the company's still-optimistic guidance. The fraud claim centers on a classic information gap: while Corcept told investors the drug was nearing approval, the FDA had reportedly warned the company multiple times about inadequate data. The bombshell came on December 31, 2025, when the FDA delivered a Complete Response Letter, triggering a 50.4% single-day stock price collapse that wiped out billions.

In this context, the recent insider move by Director James N. Wilson is telling. On March 13, 2026, Wilson made a bona fide gift of 28,000 shares to a trust. This is not a sale, but it is a transfer of wealth outside his immediate control. The timing is critical: this gift occurred after the FDA rejection and the lawsuit announcement. For an insider, such a move signals a deliberate reduction in personal skin in the game, positioning for the fallout rather than the promised growth. It suggests some executives are already hedging their bets, even if they haven't sold outright. The lawsuit's lead plaintiff deadline is April 21, 2026, meaning the legal reckoning is imminent. When the smart money starts giving away its shares, it's often a sign they've already priced in the worst.

Insider Sentiment Score: A Neutral Read in Crisis

The numbers tell a story of cautious neutrality. Corcept's insider ownership stands at 24.57%, a substantial stake held by its 45 total insiders. That's skin in the game, but the recent pattern suggests the game has changed. The company's Insider Sentiment Score of 50 is a textbook average-neither a strong signal of accumulation nor a red flag of mass selling. In a crisis, this is a neutral read, meaning the smart money isn't rushing to buy or sell.

Digging into the metrics, the picture is even more muted. In the last 90 days, the net number of insiders buying is zero, placing the company at the bottom percentile. The total shares bought by insiders as a percentage of the float is a negligible 0.045%. This isn't institutional accumulation; it's a whisper, not a roar. The score's reliance on total shares owned by insiders also reflects the high baseline ownership, which can artificially dampen the signal of recent activity.

The stock's current price of around $42.49 is a stark reminder of the lost ground. It's down from a high of over $71 earlier this year, a drop that mirrors the market's loss of faith in the relacorilant story after the FDA rejection. In this environment, a neutral sentiment score is telling. It suggests insiders are neither betting big on a turnaround nor fleeing en masse. They are holding, waiting. When the smart money is this quiet, it often means they are assessing the legal and clinical fallout, not making a call on the stock's next move. For now, the signal is simply: wait and see.

The Core Business vs. The Speculative Pipeline

The smart money is looking past the noise. Corcept's story is now two stories: a solid, growing core business and a speculative pipeline that has just hit a wall. The numbers for the core Cushing's syndrome franchise are impressive. In 2025, it delivered a 37 percent increase in tablets sold, driving full-year revenue to $761.4 million. The company is guiding for a jump to $900 – $1,000 million in 2026. This is real, cash-generating growth. The business is expanding, and the company has the balance sheet to support it, with $532.4 million in cash and investments at year-end.

Yet, the market's valuation has been brutally reset. Analyst price targets have been slashed from $145 to $90 and from $105 to $67. This isn't just a reaction to the FDA rejection; it's a fundamental reassessment of the company's future. The core business is strong, but the stock's prior run-up had already priced in that growth, plus the massive, unproven potential of the relacorilant pipeline. As UBS analyst Ashwani Verma noted when initiating coverage, the stock was already pricing in both the continued growth in hypercortisolism and Corcept's new launch opportunity in platinum-resistant ovarian cancer. The FDA's Complete Response Letter removed that future certainty.

The bottom line is a valuation disconnect. The core business is a cash cow, but its growth is now seen as a baseline, not a catalyst. The speculative pipeline-the part that could drive the stock to new highs-has been derailed. For the smart money, this creates a dilemma. The cash flow from the core business is real, but the upside from the pipeline is now uncertain and delayed. The recent insider moves, like the director's gift, suggest some insiders are already positioning for this new reality: a company with a solid but stagnant core, facing a legal overhang, and a pipeline that needs a major reset. The skin in the game is still there, but the alignment of interest has shifted from explosive growth to navigating a crisis.

Catalysts and What to Watch for Smart Money

The next few months will separate the trap from the turnaround. The primary catalyst is the FDA's response to Corcept's resubmission of the relacorilant NDA. This decision will determine the drug's fate and, by extension, the company's future. The FDA's previous Complete Response Letter revealed the agency had warned Corcept multiple times about inadequate data. The resubmission is Corcept's final chance to address those issues. For the smart money, the FDA's verdict will be the ultimate signal: a green light could reignite the speculative pipeline story, while another rejection would confirm the worst-case scenario and likely trigger further legal and financial pressure.

Alongside this regulatory event, watch for any significant insider buying or selling. The recent director's gift of 28,000 shares is a reduction in skin in the game, but it's not a sale. The real signal will be if insiders start accumulating shares again in the coming weeks or months. A pattern of net buying would suggest management has confidence in the company's ability to navigate the crisis and that the core business's cash flow provides a solid foundation. Conversely, more sales would reinforce the view that insiders are positioning for the legal and clinical fallout. The recent neutral sentiment score, with zero net buys in 90 days, shows the smart money is currently on the sidelines. Their next move will be telling.

The legal overhang is also a near-term pressure point. The lead plaintiff deadline for the class action lawsuit is April 21, 2026. This deadline could bring more legal pressure and distraction, potentially diverting management's focus from the FDA resubmission. For investors, this creates a dual catalyst: the FDA decision on the drug's future and the court's decision on the lawsuit's lead plaintiff. Both will shape the company's path forward. In the meantime, the core business continues to deliver, with 2025 revenue of $761.4 million and a strong growth trajectory. But for the stock to move meaningfully, the speculative pipeline must clear its biggest hurdle: the FDA. Until then, the smart money will be watching, waiting for a clearer signal.